Pharmacokinetics of nAdroparin in venous thromboembolism Prophylaxis in critically ill pAtients - an observational pilot study

Pharmacokinetics of nAdroparin in venous thromboembolism Prophylaxis in critically ill pAtients - an observational pilot study - The PAPA study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38854

Enrollment

Registered

2014-01-23

Start date

2014-12-02

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

deep venous thrombosis Venous thromboembolism

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * The patient is at least 18 years of age. * The patient is admitted to the intensive care unit. * The patient is already treated with nadroparin for VTE prophylaxis, or, is eligible for treatment with nadroparin for such reasons. * The patient already has a catheter to obtain the necessary blood samples.

Exclusion criteria

Exclusion criteria: * Acute and life-threatening complications that require immediate patient treatment, as decided by the intensive care physician. * The patient is admitted to the ICU for routine post-operative intensive care monitoring * The patient is treated with a therapeutic dose of nadroparin

Design outcomes

Primary

Measure	Time frame
Quantitative description of nadroparin pharmacokinetics in critically ill patients: changes in anti-Xa-time profiles and their possible relationship with critical illness	—

Secondary

Measure	Time frame
Niet van toepassing	—

Countries

Netherlands

Outcome results